Bibliografias temáticas / Resistance to therapies / Livros
Siga este link para ver outros tipos de publicações sobre o tema: Resistance to therapies.

Livros sobre o tema "Resistance to therapies"

Autor: Grafiati
Publicado: 16 de novembro de 2024

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores livros para estudos sobre o assunto "Resistance to therapies".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os livros das mais diversas áreas científicas e compile uma bibliografia correta.

1

Xavier, Ana C., e Mitchell S. Cairo, eds. Resistance to Targeted Therapies in Lymphomas. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-24424-8.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Ling, Silvia CW, e Steven Trieu, eds. Resistance to Targeted Therapies in Multiple Myeloma. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73440-4.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Villanueva, Augusto, ed. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56197-4.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Prosperi, Jenifer R., ed. Resistance to Targeted Therapies in Breast Cancer. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-70142-4.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Tivnan, Amanda, ed. Resistance to Targeted Therapies Against Adult Brain Cancers. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46505-0.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Szewczuk, Myron R., Bessi Qorri e Manpreet Sambi, eds. Current Applications for Overcoming Resistance to Targeted Therapies. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21477-7.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Ferreri, Andrés J. M., ed. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75184-9.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20741-4.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Scardino, Peter T. Targeted Therapies for Castration-Resistant Prostate Cancer. Unitec House, 2 Albert Place, London N3 1QB, UK: Future Medicine Ltd, 2011. http://dx.doi.org/10.2217/9781780840109.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Michael, Neenan, ed. Working with resistance in rational emotive behaviour therapy: A practitioner's guide. London: Routledge, 2012.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
11

Targeted Therapies: Mechanisms of Resistance. Humana, 2013.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
12

Targeted therapies: Mechanisms of resistance. New York: Humana Press, 2011.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
13

Gioeli, Daniel. Targeted Therapies: Mechanisms of Resistance. Humana Press, 2011.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
14

Cairo, Mitchell S., e Ana C. Xavier. Resistance to Targeted Therapies in Lymphomas. Springer International Publishing AG, 2020.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
15

Cairo, Mitchell S., e Ana C. Xavier. Resistance to Targeted Therapies in Lymphomas. Springer, 2019.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
16

Lasfar, Ahmed, Andrew Zloza, Karine A. Cohen-Solal e Murugabaskar Balan, eds. Tumor Microenvironment and Resistance to Current Therapies. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-283-1.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
17

Prosperi, Jenifer R. Resistance to Targeted Therapies in Breast Cancer. Springer, 2017.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
18

Ling, Silvia, e Steven Trieu. Resistance to Targeted Therapies in Multiple Myeloma. Springer International Publishing AG, 2021.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
19

Villanueva, Augusto. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Springer, 2017.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
20

Prosperi, Jenifer R. Resistance to Targeted Therapies in Breast Cancer. Springer, 2018.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
21

Villanueva, Augusto. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Springer, 2018.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
22

Ling, Silvia Cw, e Steven Trieu. Resistance to Targeted Therapies in Multiple Myeloma. Springer International Publishing AG, 2022.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
23

Szewczuk, Myron R., Bessi Qorri e Manpreet Sambi. Current Applications for Overcoming Resistance to Targeted Therapies. Springer, 2019.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
24

Ferreri, Andrés J. M. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Springer International Publishing AG, 2019.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
25

Tivnan, Amanda. Resistance to Targeted Therapies Against Adult Brain Cancers. Springer, 2016.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
26

Szewczuk, Myron R., Bessi Qorri e Manpreet Sambi. Current Applications for Overcoming Resistance to Targeted Therapies. Springer International Publishing AG, 2020.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
27

Ferreri, Andrés J. M. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Springer, 2018.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
28

Tivnan, Amanda. Resistance to Targeted Therapies Against Adult Brain Cancers. Springer, 2018.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
29

Bonavida, Benjamin. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance. Springer New York, 2015.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
30

Molecular Mechanisms Of Tumor Cell Resistance To Chemotherapy Targeted Therapies To Reverse Resistance. Springer-Verlag New York Inc., 2013.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
31

Bonavida, Benjamin. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance. Springer London, Limited, 2013.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
32

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Springer International Publishing AG, 2015.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
33

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Adis International, Limited, 2015.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
34

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne e Gareth Morris-Stiff. Targeted and biological therapies. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0009.

Texto completo da fonte
Resumo:
Hormone therapy describes the role of hormones in the growth of a variety of cancers, and the therapeutic effects of manipulation of hormone levels in these diseases. Sex hormones stimulate the growth of breast and prostate cancers, many of which respond to surgical removal of the hormone-secreting gonad. Pharmacological measures to deliver hormone therapy in these diseases include luteinising hormone releasing hormone (LHRH) agonists and antagonists, inhibitors of sex hormone synthesis, and inhibitors of hormone-receptor binding. These treatments have established benefits in both in the control of advanced disease and the adjuvant therapy of early-stage disease. The pros and cons of combination hormone therapy are discussed. Resistance to hormone therapy may be primary or acquired, and the likely mechanisms are described.
Estilos ABNT, Harvard, Vancouver, APA, etc.
35

Fraziano, Maurizio, Roberto Nisini, Gian Maria Rossolini e Marco Rinaldo Oggioni, eds. Exploiting Novel Combined Host- and Pathogen-Directed Therapies for Combating Bacterial Multidrug Resistance. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88966-307-1.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
36

Ensell, Alden. Insulin Resistance Diet - Combat Pcos Problems, Daily Food Plans, Proper Lifestyle and Tasty Recipes: Pcos and Natural Therapies. Independently Published, 2021.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
37

Poma, Alessandro, e Loris Rizzello. Nanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance. Elsevier, 2022.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
38

Poma, Alessandro, e Loris Rizzello. Nanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance. Elsevier, 2022.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
39

Howland, Robert H. Multidisciplinary Treatments and Medications for Depressive Disorders and Comorbidity. Editado por C. Steven Richards e Michael W. O'Hara. Oxford University Press, 2014. http://dx.doi.org/10.1093/oxfordhb/9780199797004.013.008.

Texto completo da fonte
Resumo:
Compared with episodic depression, chronic depression and treatment resistant depression have higher rates of comorbidity, more persistent social and vocational disability, an increased risk of suicide, greater medical morbidity and mortality, and greater health care utilization and costs. A large number of antidepressant medications and other psychotropic drugs, depression-focused psychotherapies, and neuromodulation therapies are available for the treatment of depression. Many drugs or psychotherapies are used for the treatment of other psychiatric disorders or medical conditions, and they should be considered relevant when these comorbidities exist with depression. Selecting treatments for depression must take into account the clinical implications of the presence of any comorbidities. Because comorbidity is associated with depressive chronicity and treatment resistance, various approaches to treating chronic depression or TRD have been investigated. Treating depressed patients with comorbid psychiatric, personality, or medical disorders is a clinical challenge that requires effective multidisciplinary collaboration.
Estilos ABNT, Harvard, Vancouver, APA, etc.
40

Murrough, James. Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation. Elsevier Science & Technology Books, 2024.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
41

Murrough, James. Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation. Elsevier Science & Technology, 2024.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
42

Stafstrom, Carl E. Alternative Therapies for Epilepsy. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0046.

Texto completo da fonte
Resumo:
Up to one third of patients with epilepsy suffer from seizures that are refractory to medications. For these patients, many of whom are not surgical candidates, dietary therapies provide a promising alternative. The best known dietary therapy is the ketogenic diet, which was developed in the 1920s; newer variants of the ketogenic diet, such as the medium-chain triglyceride diet, modified Atkins diet, and low glycemic index treatment, afford excellent seizure control with fewer dietary restrictions. Together, dietary approaches offer drug-resistant patients hope for seizure reduction and an improved quality of life.
Estilos ABNT, Harvard, Vancouver, APA, etc.
43

Fu, Caiyun, Yongchuan Gu, Hong Zhu, Wen Zhou e Fanfan Zhou, eds. Clinical Therapeutic Development Against Cancers Resistant to Targeted Therapies. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-428-2.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
44

Kreit, John W. Severe Obstructive Lung Disease. Editado por John W. Kreit. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190670085.003.0013.

Texto completo da fonte
Resumo:
Although chronic obstructive lung disease, asthma, bronchiectasis, and bronchiolitis have very different causes, clinical features, and therapies, they share the same underlying pathophysiology. They are referred to as obstructive lung diseases because airway narrowing causes increased resistance and slowing of expiratory gas flow. Mechanical ventilation of patients with severe obstructive lung disease often produces two problems that must be recognized and effectively managed: over-ventilation and dynamic hyperinflation. Severe Obstructive Lung Disease reviews these two major adverse consequences of mechanical ventilation in patients with severe air flow obstruction. The chapter explains how to detect and correct both of these problems and provides guidelines for managing patients with respiratory failure caused by severe obstructive lung disease.
Estilos ABNT, Harvard, Vancouver, APA, etc.
45

León-Buitimea, Angel, Jose Ruben Morones-Ramirez, Jason H. Yang e Rafael Peña-Miller, eds. Facing the Upcoming of Multidrug-Resistant and Extensively Drug-Resistant Bacteria: Novel Antimicrobial Therapies (NATs). Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-653-9.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
46

Kessler, Sudha Kilaru. The Ketogenic Diet and Related Therapies in “Novel” Situations. Editado por Eric H. Kossoff. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190497996.003.0008.

Texto completo da fonte
Resumo:
The ketogenic diet (KD) is often considered as a treatment option for medication-resistant focal epilepsies and symptomatic generalized epilepsies, but is perhaps less commonly considered for idiopathic generalized epilepsies. The evidence for the use of the KD in two common idiopathic generalized epilepsy syndromes, childhood absence epilepsy and juvenile myoclonic epilepsy, is presented here.
Estilos ABNT, Harvard, Vancouver, APA, etc.
47

Demitrack, Mark A., e Sarah H. Lisanby. Methodological issues in clinical trial design for TMS. Editado por Charles M. Epstein, Eric M. Wassermann e Ulf Ziemann. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780198568926.013.0039.

Texto completo da fonte
Resumo:
This article explores the emergence of transcranial magnetic stimulation (TMS) as a new therapeutic approach and the implications of this technology for the study and treatment of neuropsychiatric disorders, with a focus on major depression. Relapse, chronicity, and varying degrees of treatment resistance characterize major depression. A substantial number of patients are not effectively treated with pharmacology or medications alone. It is proposed that TMS, along with other device-based therapies emerging in psychiatry, may define a potential new treatment platform, with existing therapeutics for major depression. Through the example of a study, this article describes the methodological considerations in the development of TMS for the treatment of major depression. Device-based approaches to therapeutic neuromodulation hold the promise of significant clinical advantages compared to existing treatments for major depression, but evidence in well designed and properly blinded multicenter trials is still lacking, hence, research in this area is ongoing.
Estilos ABNT, Harvard, Vancouver, APA, etc.
48

Shapiro, Leslie J. Understanding OCD. ABC-CLIO, LLC, 2015. http://dx.doi.org/10.5040/9798216029649.

Texto completo da fonte
Resumo:
One of the most experienced therapists in the world for treatment-resistant obsessive compulsive disorder (OCD) explains the disorder, the treatments available, and the skills needed to overcome and outsmart OCD. This is an eye-opening study of one of the most common psychiatric ailments diagnosed today—obsessive compulsive disorder (OCD). Written by Leslie J. Shapiro, a renowned therapist at one of the most well known OCD facilities in the world, this reference shares effective treatment strategies and clinical factors for helping therapists, mental health professionals, psychology students, clergy, and others deal with patients coping with this illness. The author offers case examples from her 15 years of residential work with patients, demonstrating how sufferers—even the most treatment resistant—can get control of the condition. Organized into three sections, this guidebook first reveals how OCD and guilt are intertwined and explores survival instincts, cultural factors, and the nature of thoughts. The second section covers aspects of the obsessive conscience such as scrupulosity, moralosity, and obsessive guilt. The book’s conclusion describes effective exposure and response prevention strategies for these symptoms and examines methods of treatment that augment and help maintain recovery. An in-depth discussion on the differences between compulsive and impulsive behaviors—as well as other treatment impediments—is included.
Estilos ABNT, Harvard, Vancouver, APA, etc.
49

Mukherji, Deborah, Aurelius Omlin, Carmel Pezaro e Johann De Bono. Novel therapies and emerging strategies for the treatment of patients with castration-resistant prostate cancer. Editado por James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0069.

Texto completo da fonte
Resumo:
Castration-resistant prostate cancer (CRPC) represents a final stage of this malignancy for many men and is defined as the progression of prostate cancer despite castrate levels of testosterone. CRPC may present as a rising PSA, the development of new metastases, or worsening of known metastases. Recent advances have resulted in five new treatments for CRPC: the immunotherapy sipuleucel-T; the cytotoxic cabazitaxel; the androgen biosynthesis inhibitor abiraterone acetate; the radioisotope radium-223; and the antiandrogen enzalutamide. These have all improved overall survival in randomized phase III studies for patients with metastatic CRPC. Furthermore, multiple agents and combinations are currently in late-stage clinical testing. Men with advanced prostate cancer represent an important population for clinical and translational research and clinical trial participation should be considered as part of standard care.
Estilos ABNT, Harvard, Vancouver, APA, etc.
50

Thursfield, Rebecca, Chris Orchard, Rosanna Featherstone e Jane C. Davies. Future treatments. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198702948.003.0013.

Texto completo da fonte
Resumo:
There are only a relatively limited armoury of drugs, the majority of which are aimed at downstream symptoms of cystic fibrosis. Therapies targeting the basic defect in CF as well as continued availability of more conventional drugs are required. Progress in gene therapy has been limited by the significant barriers to gene transfer of the CF lung, but the UK is hosting a large repeated dose trial of nebulized non-viral gene therapy designed around clinically meaningful outcomes. The UK CF Gene Therapy Consortium is also seeking to develop a promising modified lentiviral approach, although this is some years off. Perhaps the exciting development of recent decades has come from small molecule CFTR modulators, driven by an understanding of basic pathophysiological mechanisms. Ivacaftor is the first drug to be licensed, having proved itself highly clinically efficacious in patients with the class-3 gating mutation G551D. The trial pipeline seeks to expand indications for this and to explore the potential of Phe508del correctors. Finally, a number of anti-inflammatory and anti-infective strategies are being pursued. The emerging global problem of antibiotic resistance is leading to exciting alternatives such as biofilm disruption and bacteriophage to be explored.
Estilos ABNT, Harvard, Vancouver, APA, etc.
Você também pode estar interessado em listas de outros tipos de fontes sobre o assunto "Resistance to therapies":
Artigos de revistas Teses / dissertações
Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!

Vá para a bibliografia